Longeveron Inc. (LGVN)
LGVNNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$3.26
-0.0409 (-1.24%) today
At the close, Nov 11, 4:00 PM ET. Pre-market $3.20 -3.05%
- Market cap
- $10.20m
- P/E
- –
- EPS, last 4 quarters
- $-9.90
- Dividend yield
- –
- Day range
- –
- 52-week range
- $1.31 to $12.30
- Average volume
- –
- Previous close
- $3.30
Analysts
2 covering1 buy, 1 hold, 0 sell
Targets a year out average $30.00, +820.5% from here
Earnings
next estimate $-1.70Next report Nov 17, 2026
Sep 2025
-50.0%
Dec 2025
+47.6%
Mar 2026
0.0%
Jun 2026
0.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | $137.0k | $365.0k | $398.0k | $287.0k |
| Gross profit | $125.0k | $257.0k | $264.0k | $182.0k |
| Operating income | -$7.31m | -$5.40m | -$4.78m | -$6.17m |
| Net income | -$7.22m | -$5.44m | -$4.74m | -$6.07m |
Last four quarters: revenue $1.19m, margin -1977.6%, free cash flow –
News
8 latest- Longeveron Inc. Reports Resignation of Director Ursula Ungaro on November 1, 2026Fintel · 6 days ago
- Longeveron Reports Fewer Cardiac Events In Phase 2b Heart Syndrome Trial After Primary Endpoint Miss RTTNews · Oct 27, 2026
- Weekly Buzz: RARE, BAYRY Win Approvals; SION Cuts Jobs, GSK Deals; AZN, RHHBY Lead RTTNews · Sep 18, 2026
- Longeveron's Laromestrocel Misses Primary Endpoint In Phase 2b HLHS Trial; Stock Down 59% RTTNews · Sep 16, 2026
- Longeveron To Enter 1-for-10 Reverse Stock Split For Minimum Bid Price Compliance; Shares Plunge RTTNews · Aug 25, 2026
- Longeveron Appoints Jhaveri As CFO Ahead Of Phase 2b Data; Stock Up RTTNews · Aug 19, 2026
- Longeveron (LGVN) Q2 2026 Earnings Call TranscriptThe Motley Fool · Aug 19, 2026
- Longeveron CFO Lisa Locklear To Step Down; Marie Washburn Appointed As Successor RTTNews · Jul 7, 2026
The company
Longeveron is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. The Company's lead investigational product is laromestrocel (Lomecel-B), an allogeneic mesenchymal stem cell (MSC) therapy product isolated from the bone marrow of young, healthy adult donors. We believe laromestrocel has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas. Laromestrocel development programs have received five distinct and important FDA designations: for the HLHS program - Orphan Drug designation, Fast Track designation, and Rare Pediatric Disease designation; and, for the AD program - Regenerative Medicine Advanced Therapy (RMAT) designation and Fast Track designation.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- longeveron.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.